Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open Label Study of the Effects of Lean Body Mass (LBM) and Proton Pump Inhibitors (PPIs) on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients

NCT02439723 is registered in ClinicalTrials.gov with AHS Cancer Control Alberta as lead sponsor.

NCT NCT02439723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02439723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open Label Study of the Effects of Lean Body Mass (LBM) and Proton Pump Inhibitors (PPIs) on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients
Lead sponsor
AHS Cancer Control Alberta
Phase
Phase 1
Overall status
Withdrawn
Start date
March 31, 2016
Completion date
December 31, 2017
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced solid malignancies, metastatic solid malignancies